Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants

Molecular Pain

Volumn 7, Issue , 2011, Pages

  Nishiyori, Michiko ^a   Uchida, Hitoshi ^a   Nagai, Jun ^a   Araki, Kohei ^a   Mukae, Takehiro ^a   Kishioka, Shiroh ^b   Ueda, Hiroshi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Allodynia; Antidepressant; Cold stress; Fibromyalgia; Hyperalgesia; Vicious circle

Indexed keywords

AMITRIPTYLINE; CORTICOSTERONE; MIANSERIN; MILNACIPRAN; PAROXETINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT;

ALLODYNIA; ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; COLD STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DOSE RESPONSE; FIBROMYALGIA; HYPERALGESIA; MALE; MOUSE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; COLD; DRUG EFFECT; INTRASPINAL DRUG ADMINISTRATION; PAIN; PHYSIOLOGICAL STRESS;

ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BODY WEIGHT; COLD TEMPERATURE; CORTICOSTERONE; DEPRESSION; FIBROMYALGIA; HYPERALGESIA; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED C57BL; PAIN; STRESS, PHYSIOLOGICAL;

EID: 80053173337     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-7-69     Document Type: Article

References (56)

1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38(1):19-28.
2. Schmidt-Wilcke T, Clauw DJ. Pharmacotherapy in fibromyalgia (FM)--implications for the underlying pathophysiology. Pharmacol Ther 127(3):283-294.
3. Jensen KB, Kosek E, Petzke F, Carville S, Fransson P, Marcus H, Williams SC, Choy E, Giesecke T, Mainguy Y, et al. Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain 2009, 144(1-2):95-100.
4. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005, 114(1-2):295-302.
5. Clauw DJ. Fibromyalgia: an overview. Am J Med 2009, 122(12 Suppl):S3-S13.
6. Arnold LM, Bradley LA, Clauw DJ, Glass JM, Goldenberg DL. Multidisciplinary care and stepwise treatment for fibromyalgia. J Clin Psychiatry 2008, 69(12):e35.
7. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE, Welge JA, Bishop F, Stanford KE, Hess EV, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007, 56(4):1336-1344.
8. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Sharma U, Martin SA, Barrett JA, Haig G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008, 9(9):792-805.
9. Sluka KA, Kalra A, Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2001, 24(1):37-46.
10. Khasar SG, Miao JP, Janig W, Levine JD. Modulation of bradykinin-induced mechanical hyperalgesia in the rat by activity in abdominal vagal afferents. Eur J Neurosci 1998, 10(2):435-444.
11. Khasar SG, Dina OA, Green PG, Levine JD. Sound Stress-Induced Long-Term Enhancement of Mechanical Hyperalgesia in Rats Is Maintained by Sympathoadrenal Catecholamines. J Pain 2009, 10(10):1073-1077.
12. Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain 2009, 146(1-2):26-33.
13. Nishiyori M, Ueda H. Prolonged gabapentin analgesia in an experimental mouse model of fibromyalgia. Mol Pain 2008, 4:52.
14. Nishiyori M, Nagai J, Nakazawa T, Ueda H. Absence of morphine analgesia and its underlying descending serotonergic activation in an experimental mouse model of fibromyalgia. Neurosci Lett 2010, 472(3):184-187.
15. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16(2):109-110.
16. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980, 67(2-3):313-316.
17. Inoue M, Mishina M, Ueda H. Locus-specific rescue of GluRepsilon1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. J Neurosci 2003, 23(16):6529-6536.
18. Zenker N, Bernstein DE. The estimation of small amounts of corticosterone in rat plasma. J Biol Chem 1958, 231(2):695-701.
19. Pellow S. Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid?. Methods Find Exp Clin Pharmacol 1986, 8(9):557-565.
20. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85(3):367-370.
21. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32(1):77-88.
22. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004, 10(7):712-718.
23. Kita T, Hata T, Iida J, Yoneda R, Isida S. Decrease in pain threshold in SART stressed mice. Jpn J Pharmacol 1979, 29(3):479-482.
24. Smith HS, Harris R, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician 14(2):E217-245.
25. Khasar SG, Green PG, Levine JD. Repeated sound stress enhances inflammatory pain in the rat. Pain 2005, 116(1-2):79-86.
26. Yunus MB. The role of gender in fibromyalgia syndrome. Curr Rheumatol Rep 2001, 3(2):128-134.
27. Khasar SG, Burkham J, Dina OA, Brown AS, Bogen O, Alessandri-Haber N, Green PG, Reichling DB, Levine JD. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci 2008, 28(22):5721-5730.
28. Imbe H, Iwai-Liao Y, Senba E. Stress-induced hyperalgesia: animal models and putative mechanisms. Front Biosci 2006, 11:2179-2192.
29. Ohara H, Kawamura M, Namimatsu A, Miura T, Yoneda R, Hata T. Mechanism of hyperalgesia in SART stressed (repeated cold stress) mice: antinociceptive effect of neurotropin. Jpn J Pharmacol 1991, 57(2):243-250.
30. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229(2):327-336.
31. Hata T, Nishikawa H, Itoh E, Watanabe A. Depressive state with anxiety in repeated cold-stressed mice in forced swimming tests. Jpn J Pharmacol 1999, 79(2):243-249.
32. Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, Vakfari A, Kouvelas D. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther 35(6):639-656.
33. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin - A meta-analysis of randomized controlled trials. Pain 2009, 145(1-2):69-81.
34. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP, LaMoreaux LK, Martin SA, Sharma U. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52(4):1264-1273.
35. Rao SG, Bennett RM. Pharmacological therapies in fibromyalgia. Best Pract Res Clin Rheumatol 2003, 17(4):611-627.
36. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005, 32(10):1975-1985.
37. Arnold LM, Hudson JI, Wang F, Wohlreich MM, Prakash A, Kajdasz DK, Chappell AS. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. Clin J Pain 2009, 25(6):461-468.
38. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 2000, 1(4):310-316.
39. Millan MJ. Descending control of pain. Prog Neurobiol 2002, 66(6):355-474.
40. Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Kruger M, Schoeps P, Ackenheil M. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999, 42(11):2482-2488.
41. Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol 2002, 21(3):194-197.
42. Tander B, Gunes S, Boke O, Alayli G, Kara N, Bagci H, Canturk F. Polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase genes: a study on fibromyalgia susceptibility. Rheumatol Int 2008, 28(7):685-691.
43. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum Psychopharmacol 2009, 24(Suppl 1):S19-23.
44. Banerjee SP, Kung LS, Riggi SJ, Chanda SK. Development of beta-adrenergic receptor subsensitivity by antidepressants. Nature 1977, 268(5619):455-456.
45. Wolfe BB, Harden TK, Sporn JR, Molinoff PB. Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther 1978, 207(2):446-457.
46. Antkiewicz-Michaluk L, Romanska I, Michaluk J, Vetulani J. Role of calcium channels in effects of antidepressant drugs on responsiveness to pain. Psychopharmacology (Berl) 1991, 105(2):269-274.
47. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999, 42(12):2561-2568.
48. Petrie RX, Reid IC, Stewart CA. The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review. Pharmacol Ther 2000, 87(1):11-25.
49. Wattiez AS, Libert F, Privat AM, Loiodice S, Fialip J, Eschalier A, Courteix C. Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: prediction for efficacy in animal models of neuropathic pain?. Br J Pharmacol 163(4):792-803.
50. Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 2006, 8(4):212.
51. Tzellos TG, Papazisis G, Toulis KA, Sardeli C, Kouvelas D. A2delta ligands gabapentin and pregabalin: future implications in daily clinical practice. Hippokratia 14(2):71-75.
52. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995, 24(6):360-365.
53. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007, 27(37):10000-10006.
54. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterisation of acid-induced muscle allodynia in rats. Eur J Pharmacol 2004, 487(1-3):93-103.
55. Sluka KA, Rohlwing JJ, Bussey RA, Eikenberry SA, Wilken JM. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists. J Pharmacol Exp Ther 2002, 302(3):1146-1150.
56. Furuta S, Shimizu T, Narita M, Matsumoto K, Kuzumaki N, Horie S, Suzuki T. Subdiaphragmatic vagotomy promotes nociceptive sensitivity of deep tissue in rats. Neuroscience 2009, 164(3):1252-1262.